InnoSkel is a biotechnology company developing targeted gene therapies for rare skeletal diseases, utilizing advanced CRISPR technology to correct genetic mutations. Their approach aims to improve patient outcomes by addressing the underlying genetic causes of these conditions, which currently lack effective treatment options.
Funding
$24.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
JCFounders
Product
Problem
Rare skeletal diseases often lack effective treatment options, leaving patients with limited means to address the underlying genetic causes of their conditions. Current approaches may not target the specific genetic mutations responsible for these diseases, resulting in suboptimal outcomes.
Solution
InnoSkel is developing targeted gene therapies for rare skeletal diseases by leveraging advanced CRISPR technology to correct the responsible genetic mutations. This approach aims to improve patient outcomes by directly addressing the root cause of these conditions. By precisely editing the genome, InnoSkel's therapies offer the potential for long-term correction and disease modification, unlike traditional treatments that only manage symptoms. The company's focus is on developing innovative solutions for diseases with significant unmet medical needs.
Target Audience
The primary target audience includes patients suffering from rare skeletal diseases and their families, as well as medical professionals specializing in genetics and skeletal disorders.
Features
- Utilizes CRISPR technology for precise gene editing
- Focuses on correcting genetic mutations underlying rare skeletal diseases
- Aims for long-term disease modification rather than symptom management
- Develops targeted therapies for specific genetic defects